{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phenylephrine&page=7",
    "query": {
      "intervention": "Phenylephrine",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 252,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phenylephrine&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phenylephrine&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T04:38:33.977Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03380390",
      "title": "Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Oxymetazoline HCL 1.0% Cream",
          "type": "DRUG"
        },
        {
          "name": "Energy-Based Therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2017-12-04",
      "completion_date": "2018-06-15",
      "has_results": true,
      "last_update_posted_date": "2019-09-04",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 4,
      "location_summary": "Sacramento, California • Chestnut Hill, Massachusetts • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380390"
    },
    {
      "nct_id": "NCT05923840",
      "title": "Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postural Orthostatic Tachycardia Syndrome",
        "Hypocapnia",
        "Hyperventilation"
      ],
      "interventions": [
        {
          "name": "Chemoreflex Testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Baroreflex testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Orthostatic stress testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "15 Years to 39 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2022-09-23",
      "completion_date": "2024-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05923840"
    },
    {
      "nct_id": "NCT00749385",
      "title": "A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Arthritis"
      ],
      "interventions": [
        {
          "name": "PN 400",
          "type": "DRUG"
        },
        {
          "name": "EC naproxen plus EC esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "EC naproxen",
          "type": "DRUG"
        },
        {
          "name": "EC esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "POZEN",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-08",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2008-12-23",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749385"
    },
    {
      "nct_id": "NCT04587713",
      "title": "Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Intestinal Disorder",
        "Bowel Diseases, Inflammatory"
      ],
      "interventions": [
        {
          "name": "TD-1473 [Tablet A]",
          "type": "DRUG"
        },
        {
          "name": "TD-1473 [Tablet B]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravance Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 58,
      "start_date": "2020-10-16",
      "completion_date": "2020-12-27",
      "has_results": false,
      "last_update_posted_date": "2021-04-09",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 2,
      "location_summary": "Cypress, California • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04587713"
    },
    {
      "nct_id": "NCT02062710",
      "title": "Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cough Reflex Sensitivity"
      ],
      "interventions": [
        {
          "name": "diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan",
          "type": "DRUG"
        },
        {
          "name": "dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo",
          "type": "DRUG"
        },
        {
          "name": "dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa",
          "type": "DRUG"
        },
        {
          "name": "placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan",
          "type": "DRUG"
        },
        {
          "name": "placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02062710"
    },
    {
      "nct_id": "NCT02851212",
      "title": "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin Extended Release (XR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-12-02",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02851212"
    },
    {
      "nct_id": "NCT01645085",
      "title": "A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "MCC-based 13% drug loaded tablets",
          "type": "DRUG"
        },
        {
          "name": "Mannitol-based 38% drug-loaded tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 88,
      "start_date": "2012-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-19",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01645085"
    },
    {
      "nct_id": "NCT01913002",
      "title": "Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LX4211 800 mg",
          "type": "DRUG"
        },
        {
          "name": "LX4211 2000 mg",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin 400 mg",
          "type": "DRUG"
        },
        {
          "name": "LX4211 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2013-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01913002"
    },
    {
      "nct_id": "NCT01080612",
      "title": "A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "330 mg pregabalin controlled release",
          "type": "DRUG"
        },
        {
          "name": "300 mg pregabalin immediate release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-04",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-29",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01080612"
    },
    {
      "nct_id": "NCT04858178",
      "title": "Transcutaneous Spinal Cord Neuromodulation to Normalize Autonomic Phenotypes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Autonomic Imbalance",
        "Autonomic Dysreflexia",
        "Orthostatic; Hypotension, Neurogenic"
      ],
      "interventions": [
        {
          "name": "Tests of sympathetic inhibition",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Tests of sympathetic activation",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Testing of autonomic dysreflexia",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Transcutaneous spinal cord stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DEVICE"
      ],
      "sponsor": "Spaulding Rehabilitation Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 4,
      "start_date": "2022-02-17",
      "completion_date": "2022-11-14",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-19T04:38:33.977Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04858178"
    }
  ]
}